In exemplifying the site specific PEGylation technology with single domain antibodies and interferons, Almac has demonstrated that therapeutically important complex biological proteins can be ...
San Carlos, Calif., April 9, 2007 -- Innovative pulmonary and PEGylation-based therapeutic product development is the focus of two new business units recently created at Nektar Therapeutics (Nasdaq: ...
SAN CARLOS, Calif., May 16 -- Nektar Therapeutics (Nasdaq: NKTR) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity ...
PEGylation has been around for 30 years and it is surprising that it is still widely used given the significant advances that have been made in biopharmaceutical manufacture since then. So why is this ...
Pro Bono Bio Group (PBB) exercised an option to take out an exclusive, global license to PolyTherics’ TheraPEG™ platform for use in the development and commercialization of a TheraPEG-FVIII product ...
Acquisition will add PolyPEG and GlycoPol technologies to existing PEGylation platforms. U.K. firm PolyTherics has acquired Warwick Effect Polymers (WEP), which provides specialty biopolymers based on ...
Polyethylene glycol (PEG) conjugation is a highly effective technical and commercial strategy to develop macromolecules. The authors explain the benefits and process of PEGylation and how it may be ...
SAN CARLOS, Calif., May 22 Nektar Therapeutics(Nasdaq: NKTR) announced today that Bharatt Chowrira, Ph.D., J.D. has joinedthe Company as Chief Operating Officer and Head of the PEGylation BusinessUnit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results